Michaela J. Higgins, MRCPI

home / authors / michaela-j-higgins-mrcpi

Articles

New Directions in the Systemic Treatment of Metastatic Thyroid Cancer

Michaela J. Higgins, MRCPI;Arlene A. Forastiere, MD;Shanthi Marur, MD

August 14th 2009

About 30,000 new cases of thyroid cancer are diagnosed annually in the United States.[1] The incidence among men has risen more dramatically than any other malignancy in recent years (2.4% annual increase).[2] Thyroid cancers arise from one of two cell types, namely follicular and parafollicular cells.

Adjuvant Endocrine Therapy for Premenopausal Hormone Receptor–Positive Breast Cancer: Much Done, More to Do

Michaela J. Higgins, MRCPI;Antonio C. Wolff, MD, FACP

January 2nd 2009

Based on the 1995 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Overview, tamoxifen is now the standard of care for premenopausal women with hormone receptor–positive early breast cancers.[1]

Therapeutic Options in the Management of Metastatic Breast Cancer

Michaela J. Higgins, MRCPI;Antonio C. Wolff, MD, FACP

May 1st 2008

Novel agents are adding to the wide choices of standard chemotherapies already available. This review offers an approach to the selection of individualized and rational therapies for patients with metastatic breast cancer.